We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Viatris to Pay $335 Million for Settlement of Opioid-Related Claims
Read MoreHide Full Article
Viatris, Inc. (VTRS - Free Report) announced that it has reached a nationwide settlement framework to resolve opioid-related claims by states, local governments, and tribes against it and certain of its subsidiaries.
Per the terms of the settlement agreement, Viatris would pay up to a maximum of $335 million to all the above-mentioned parties. This sum consists of annual payments of approximately $27.5-$40 million to each party over a period of nine years to help support state and local efforts to address opioid-related issues.
However, Viatris stated that the settlement is in no way an admission of wrongdoing or liability.
VTRS’ share price has plunged 38.1% year to date compared with the industry’s 4.6% decline.
Image Source: Zacks Investment Research
More on Viatris’ Opioid Litigation
Viatris, along with other manufacturers, distributors, pharmacies, pharmacy benefit managers and individual healthcare providers, is a defendant in more than 1,000 cases in the United States and Canada filed by various plaintiffs who seek damages and relief.
VTRS and many other pharma companies were accused of not stating the health risks of opioid-related medications.
In addition, lawsuits have been filed as putative class actions, including on behalf of children with Neonatal Abstinence Syndrome due to alleged exposure to opioids.
Viatris accrued approximately $270 million as of Dec. 31, 2024, in connection with the possible resolution of certain of these matters, which is included in other current liabilities in the consolidated balance sheets.
Viatris was formed through the merger of the erstwhile Mylan and Pfizer’s (PFE - Free Report) Upjohn businesses.
The company has agreed to pay Pfizer approximately 57% of any loss actually incurred or suffered by the former, its predecessors or subsidiaries since 2019, arising out of third-party actions relating to the manufacture, distribution, marketing, promotion or sale of opioids by or on behalf of Viatris, its predecessors or subsidiaries.
VTRS currently manufactures a generic injectable version of the life-saving overdose reversal drug, naloxone, as well as a generic buprenorphine/naloxone product used for the treatment of opioid addiction. It is also developing a novel delivery for meloxicam, a non-opioid pain medication.
Challenges Confronting Viatris
In February, VTRS reported lower-than-expected fourth-quarter results, wherein the top and bottom lines missed their respective estimates. The guidance for 2025 was disappointing as well.
Following an inspection of Viatris' oral finished dose manufacturing facility in Indore, India, in June 2024, the company received a warning letter and import alert from the FDA in December 2024.
The import alert affects 11 actively distributed products, including lenalidomide and everolimus. However, the regulatory body made exceptions for four products based on shortage concerns.
While these products continue to be shipped from the Indore facility to markets outside the United States, VTRS currently anticipates some impact in other markets. Due to this, VTRS estimates 2025 revenues to be negatively impacted by approximately $500 million.
In the past 60 days, ADMA’s earnings per share (EPS) estimates for 2025 have increased to 71 cents from 69 cents in the past 60 days. The EPS estimate for 2026 has increased to 93 cents from 87 cents in the same time frame. Shares of ADMA have gained 7.3% year to date.
BMRN’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 32.36%.
The Zacks Consensus Estimate for BMRN’s 2025 EPS has increased to $4.30 from $4.01 in the past 60 days. The consensus mark for 2026 EPS has risen 15 cents to $5.35 in the said time frame.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Viatris to Pay $335 Million for Settlement of Opioid-Related Claims
Viatris, Inc. (VTRS - Free Report) announced that it has reached a nationwide settlement framework to resolve opioid-related claims by states, local governments, and tribes against it and certain of its subsidiaries.
Per the terms of the settlement agreement, Viatris would pay up to a maximum of $335 million to all the above-mentioned parties. This sum consists of annual payments of approximately $27.5-$40 million to each party over a period of nine years to help support state and local efforts to address opioid-related issues.
However, Viatris stated that the settlement is in no way an admission of wrongdoing or liability.
VTRS’ share price has plunged 38.1% year to date compared with the industry’s 4.6% decline.
Image Source: Zacks Investment Research
More on Viatris’ Opioid Litigation
Viatris, along with other manufacturers, distributors, pharmacies, pharmacy benefit managers and individual healthcare providers, is a defendant in more than 1,000 cases in the United States and Canada filed by various plaintiffs who seek damages and relief.
VTRS and many other pharma companies were accused of not stating the health risks of opioid-related medications.
In addition, lawsuits have been filed as putative class actions, including on behalf of children with Neonatal Abstinence Syndrome due to alleged exposure to opioids.
Viatris accrued approximately $270 million as of Dec. 31, 2024, in connection with the possible resolution of certain of these matters, which is included in other current liabilities in the consolidated balance sheets.
Viatris was formed through the merger of the erstwhile Mylan and Pfizer’s (PFE - Free Report) Upjohn businesses.
The company has agreed to pay Pfizer approximately 57% of any loss actually incurred or suffered by the former, its predecessors or subsidiaries since 2019, arising out of third-party actions relating to the manufacture, distribution, marketing, promotion or sale of opioids by or on behalf of Viatris, its predecessors or subsidiaries.
VTRS currently manufactures a generic injectable version of the life-saving overdose reversal drug, naloxone, as well as a generic buprenorphine/naloxone product used for the treatment of opioid addiction. It is also developing a novel delivery for meloxicam, a non-opioid pain medication.
Challenges Confronting Viatris
In February, VTRS reported lower-than-expected fourth-quarter results, wherein the top and bottom lines missed their respective estimates. The guidance for 2025 was disappointing as well.
Viatris Inc. Price, Consensus and EPS Surprise
Viatris Inc. price-consensus-eps-surprise-chart | Viatris Inc. Quote
Following an inspection of Viatris' oral finished dose manufacturing facility in Indore, India, in June 2024, the company received a warning letter and import alert from the FDA in December 2024.
The import alert affects 11 actively distributed products, including lenalidomide and everolimus. However, the regulatory body made exceptions for four products based on shortage concerns.
While these products continue to be shipped from the Indore facility to markets outside the United States, VTRS currently anticipates some impact in other markets. Due to this, VTRS estimates 2025 revenues to be negatively impacted by approximately $500 million.
Zacks Rank and Stocks to Consider
Viatris currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the sector are ADMA Biologics (ADMA - Free Report) and BioMarin Pharmaceutical (BMRN - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, ADMA’s earnings per share (EPS) estimates for 2025 have increased to 71 cents from 69 cents in the past 60 days. The EPS estimate for 2026 has increased to 93 cents from 87 cents in the same time frame. Shares of ADMA have gained 7.3% year to date.
BMRN’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 32.36%.
The Zacks Consensus Estimate for BMRN’s 2025 EPS has increased to $4.30 from $4.01 in the past 60 days. The consensus mark for 2026 EPS has risen 15 cents to $5.35 in the said time frame.